Finerenone in Asian patients with diabetic kidney disease: evaluating the evidence for "better efficacy"

Diabetic kidney disease (DKD) has emerged as the primary driver of kidney failure across the Asia-Pacific region. Thus, therapeutic interventions capable of effectively slowing the progression of chronic kidney disease (CKD) and reducing concomitant cardiovascular risk are of critical strategic importance. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (nsMRA) approved for the treatment of DKD, exerts cardiorenal protective effects by selectively inhibiting the overactivation of the mineralocorticoid receptor (MR)-a key mediator of pathological inflammatory and fibrotic processes underlying renal and cardiac injury. A consistent finding across major clinical trials, including FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis, is the "potentially enhanced" (based on post-hoc subgroup analyses) therapeutic efficacy of finerenone in Asian, predominantly Chinese, patient populations. This review synthesizes emerging evidence indicating a distinct, potentially superior therapeutic response (based on available subgroup analyses) in Asian cohorts compared to global populations, alongside potential genetic and environmental factors contributing to this phenomenon. Additionally, we address the associated safety profile of hyperkalemia in Asian patients. We contend that this risk is manageable through structured monitoring and should not preclude clinicians from utilizing this high-impact therapy. Ultimately, this review positions finerenone as a crucial and effective intervention for Asian patients with high cardiorenal risk, provided that potassium homeostasis is proactively managed.